
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Pharmingen™ PE Rat Anti-Human CD210a
Clone 3F9 (RUO)




Flow cytometric profile of CD210a expression on human peripheral blood lymphocytes. Human whole blood was stained with either PE Rat IgG2a, κ Isotype Control (Cat. No. 555844; dashed line histogram) or PE Rat Anti-Human CD210a (Cat. No. 556013; solid line histogram). Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed on a BD FACSCan™ System.


BD Pharmingen™ PE Rat Anti-Human CD210a

Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products





The 3F9 monoclonal antibody specifically binds to CD210a, which is also known as, Interleukin-10 Receptor subunit alpha (IL-10R subunit alpha/IL-10Rα/IL10RA), or Interleukin-10 receptor subunit 1 (IL-10R1). CD210a is a 90-110 kDa type I transmembrane glycoprotein that belongs to the type II cytokine receptor family. CD210a combines with IL-10 Receptor subunit beta (IL-10Rβ/IL10RB/CDw210b) to form the IL-10 Receptor complex (IL-10Rα/IL-10Rβ) that can bind IL-10 and transduce signals intracellularly through the JAK/STAT pathway. IL-10 can suppress antigen presentation and the expression of proinflammatory type-1 immune responses while promoting type-2 immune responses. CD210a is expressed on T cells, B cells, NK cells, monocyte, macrophages and dendritic cells. Clone 3F9 is specific for human CD210a and its binding to the receptor can be blocked by recombinant human IL-10 (rhIL-10) protein.

Development References (4)
-
Callard R, Gearing A. Callard R, Gearing A. The Cytokine Facts Book. San Diego: Academic Press; 1994.
-
Carson WE, Lindemann MJ, Baiocchi R, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood. 1995; 85(12):3577-3585. (Biology). View Reference
-
Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol. 1995; 152(4):1821-1829. (Biology). View Reference
-
Liu Y, de Waal Malefyt R, Briere F, et al. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor.. J Immunol. 1997; 158(2):604-13. (Immunogen: Blocking, Flow cytometry, Functional assay, Immunoprecipitation, Inhibition). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.
Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.